Rhythm Pharmaceuticals, Inc. entered into a Sales Agreement with Cowen and Company, LLC to issue and sell shares of its common stock for up to $100.0 million, with $50.0 million already sold. The proceeds will be used for commercialization efforts and clinical development programs.